Загрузка...
Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs
Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kin...
Сохранить в:
| Опубликовано в: : | ChemMedChem |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6151264/ https://ncbi.nlm.nih.gov/pubmed/27706901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201600417 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|